Millions of Americans living with diabetes trusted Dexcom’s continuous glucose monitors to keep them safe. Now, a cascade of federal recalls, a landmark consolidated class action, investor fraud claims, and heartbreaking wrongful death suits are raising urgent questions about whether those devices delivered on that promise. With Dexcom ceasing G6 manufacturing on July 1, 2026 — the exact week this post publishes — and the consolidated federal litigation at a decisive inflection point, anyone who used a Dexcom G6 or G7 needs to understand what is unfolding and what legal rights may be available.
What Is the Dexcom Lawsuit and Why Does It Matter in 2026?
The Dexcom lawsuit landscape encompasses several parallel legal tracks that converged dramatically in mid-2026. At its core, plaintiffs allege that Dexcom’s G6 and G7 continuous glucose monitors (CGMs) were defectively designed and manufactured, producing dangerously inaccurate blood glucose readings that failed to alert users to life-threatening hypoglycemia, hyperglycemia, diabetic ketoacidosis (DKA), seizures, coma, and death. These are not minor calibration disputes — for insulin-dependent diabetics relying on real-time CGM data to make dosing decisions, an inaccurate reading can be fatal.
The FDA’s medical device recall database documents the severity of reported failures, and the agency’s own enforcement actions against Dexcom have added significant regulatory weight to the civil litigation now moving through federal court. For patients evaluating whether they have a claim, understanding how these overlapping legal and regulatory developments connect is critical.
FDA Enforcement Actions: Warning Letters and Three Class I Recalls
The March 2026 FDA Adulteration Warning Letter
In March 2026, the FDA issued a formal warning letter to Dexcom following inspections of the company’s San Diego and Mesa, Arizona manufacturing facilities. The agency found G6 and G7 devices “adulterated” under federal law, citing unauthorized material changes to sensor resistance layers that caused “significantly greater variability” in glucose readings. An adulteration finding is among the FDA’s most serious enforcement designations, signaling that a device does not conform to its cleared specifications — a finding that plaintiff attorneys in the Dexcom lawsuit have characterized as direct evidence of systemic manufacturing failures.
Three Separate Class I Recalls in Twelve Months
The FDA’s highest-severity recall classification — Class I, meaning a reasonable probability of serious adverse health consequences or death — was applied to Dexcom devices three separate times in a compressed period. In June 2026, Dexcom issued an Urgent Medical Device Correction, escalated by the FDA on June 16, 2026, covering 602,445 G7 receivers and 36,824 G6 receivers worldwide. The defect involved faulty foam causing the speaker to lose contact with the circuit board, silencing critical glucose alerts. The recall was linked to 56 documented adverse events. A second Class I recall followed for G7 Android, iOS, and watchOS apps due to a software design error that prevented “Sensor Failed” alerts from reaching users. A third recall covered 333 G6 CGMs after Android mobile apps could crash, halting glucose data transmission and disabling alarms entirely. Separately, the FDA’s MedWatch adverse event reporting system has received over 500,000 adverse event reports related to the Dexcom G6 alone, with 13 reports linked to fatalities.
| Event | Date | Scope / Details | Classification |
|---|---|---|---|
| FDA Adulteration Warning Letter | March 2026 | G6 & G7; unauthorized sensor resistance layer changes; “significantly greater variability” | FDA Warning Letter |
| G7 Receiver / G6 Receiver Recall | June 16, 2026 | 602,445 G7 + 36,824 G6 receivers; defective foam silencing speaker alerts; 56 adverse events | Class I Recall |
| G7 App Recall (Android/iOS/watchOS) | September 2026 | Software error blocking “Sensor Failed” alerts; G7 and One+ CGM apps | Class I Recall |
| G6 Android App Recall | October 2026 | 333 G6 CGMs; app crashes stopping glucose data and alarms | Class I Recall |
| FDA MAUDE Adverse Events (G6) | Cumulative through 2026 | 500,000+ reports; 13 fatality-linked; 56+ severe events including seizures/loss of consciousness | Regulatory Database |
| FDA Software Safety Flag | January 2026 | Serious software issues in Dexcom glucose monitoring app; further reliability concerns raised | FDA Safety Communication |
| G6 Manufacturing Cessation | July 1, 2026 | Dexcom ended all G6 production; announced December 2025 | Corporate Action |
In re: Dexcom CGM Litigation: The Consolidated Federal Class Action
How the Cases Came Together
Between September 29, 2026, and January 8, 2026, six overlapping putative class action complaints were filed by G6 and G7 users in federal and California state court. On May 15, 2026, the U.S. District Court for the Southern District of California consolidated five of those federal cases into In re: Dexcom CGM Litigation, Case No. 3:25-cv-02565-BJC-JAC. The Los Angeles Superior Court state court action was stayed in favor of the federal proceeding. Competing motions to appoint interim class counsel were filed on May 29, 2026, are fully briefed, and remain pending before the court. A joint status report is due August 19, 2026 — making the weeks immediately following this post’s publication a pivotal window for the litigation’s direction. The Federal Rules of Civil Procedure governing class certification will be central to determining how broadly these consumer claims can proceed.
What the Class Action Alleges
The consolidated Dexcom lawsuit plaintiffs allege that Dexcom knew or should have known that its G6 and G7 devices were producing unreliable glucose readings, yet continued to market them as life-saving safety tools. Claims span defective design, manufacturing defects, failure to warn, breach of warranty, and consumer protection violations. If class certification is denied, legal analysts have flagged that plaintiffs could pursue a federal multidistrict litigation (MDL) petition — a procedural step that would centralize individual cases before a single judge for coordinated pretrial proceedings, dramatically increasing pressure on Dexcom to negotiate a resolution. For patients wondering how to evaluate potential compensation, a medical malpractice calculator can provide an initial framework for understanding defective device injury damages.
Investor Securities Class Action: Fraud Allegations Against Dexcom
The Dexcom lawsuit ecosystem extends beyond injured patients. A parallel securities class action was filed in November 2026 on behalf of investors who purchased Dexcom (NASDAQ: DXCM) securities between January 8, 2024, and September 17, 2026. The complaint alleges that Dexcom made materially false and misleading statements about the accuracy and safety of its CGM devices during this period — statements that artificially inflated the company’s stock price. Lead plaintiff Union Asset Management Holding AG was appointed on January 21, 2026, and an Amended Consolidated Complaint was filed on April 10, 2026, by Bernstein Litowitz Berger & Grossmann LLP. Securities fraud class actions operate under the Private Securities Litigation Reform Act, which sets specific procedural requirements for lead plaintiff appointment and pleading standards — standards that Union Asset Management’s amended complaint is now designed to meet.
Wrongful Death Lawsuits: The Human Cost of Alleged CGM Failures
Among the most devastating elements of the Dexcom lawsuit litigation are the wrongful death cases documenting alleged fatal device failures. Jennifer Wisdom-Schepers filed suit alleging her husband Michael used the G7 in conjunction with an insulin pump. According to the complaint, the G7 displayed normal blood glucose levels while his actual glucose was 1,651 mg/dL — a potentially fatal concentration. Michael suffered a heart attack and died. In a separate case, James Burdick filed suit in Elbert County, Colorado in December 2026, alleging his 18-year-old son Jake — a Type 1 diabetic — died in May 2024 after an undetected hyperglycemic episode while using the G6. That case was removed to the U.S. District Court for the District of Colorado on February 5, 2026. A third wrongful death suit brought by Joseph Higginbottom alleges the G6 inaccurately read glucose as dangerously high, causing the victim to administer excessive insulin; the victim lost consciousness while driving, crashed, and died. Families navigating these devastating losses may find it useful to consult a wrongful death calculator to understand how courts typically evaluate fatal defective product claims.
Dexcom Ends G6 Production July 1, 2026: What It Means for Litigation
Dexcom announced in December 2026 that it would cease all G6 manufacturing effective July 1, 2026 — a date that coincides precisely with the publication of this post. While Dexcom framed the decision as a planned product transition toward the G7 platform, plaintiff attorneys have noted the conspicuous timing: the G6 production halt arrives while the company faces three Class I recalls, a federal adulteration warning letter, a consolidated federal class action, a securities fraud suit, and multiple wrongful death cases — all centered substantially on G6 performance. Product discontinuation does not eliminate liability for devices already distributed or injuries already suffered. Courts have consistently held that manufacturers cannot extinguish civil claims by retiring a product line. The Dexcom lawsuit plaintiffs who used G6 devices retain full legal standing regardless of the July 1, 2026 production cessation.
Who May Have a Dexcom Lawsuit Claim?
Based on the allegations in the consolidated litigation and the documented recall populations, individuals who may have viable claims include: Type 1 or Type 2 diabetics who used a Dexcom G6 or G7 CGM and experienced hypoglycemic or hyperglycemic episodes not detected by the device; patients who received inaccurate glucose readings leading to incorrect insulin dosing; users who experienced seizures, loss of consciousness, diabetic ketoacidosis, or hospitalization while using a Dexcom CGM; families who lost a loved one whose diabetes management relied on a G6 or G7 device; and investors who purchased DXCM securities between January 8, 2024, and September 17, 2026. The Dexcom lawsuit is a mass tort proceeding, meaning that individual damages vary significantly based on the severity of injury, duration of device use, and specific circumstances. Patients who suffered non-fatal but serious injuries may also benefit from reviewing a personal injury settlement calculator to understand general compensation benchmarks for device-related injuries.
Frequently Asked Questions About the Dexcom Lawsuit
What is the Dexcom lawsuit about?
The Dexcom lawsuit refers to a body of consumer class action complaints, wrongful death suits, and a parallel investor securities case alleging that Dexcom’s G6 and G7 continuous glucose monitors were defectively designed and manufactured, producing inaccurate blood glucose readings that failed to alert users to life-threatening conditions including hypoglycemia, hyperglycemia, diabetic ketoacidosis, seizures, coma, and death. Five federal consumer cases were consolidated into In re: Dexcom CGM Litigation, No. 3:25-cv-02565-BJC-JAC, on May 15, 2026, in the Southern District of California.
What are the Dexcom G6 and G7 recalls?
The FDA issued three separate Class I recalls — its highest-severity classification — covering Dexcom G6 and G7 devices. The June 2026 recall covered 602,445 G7 receivers and 36,824 G6 receivers due to defective foam causing speaker failures and silent alerts. A second recall targeted G7 app software that blocked “Sensor Failed” notifications. A third covered 333 G6 CGMs after Android apps could crash and stop transmitting glucose data. Additionally, the FDA issued a formal adulteration warning letter in March 2026 finding unauthorized changes to sensor resistance layers caused significantly greater variability in readings.
Who can file a Dexcom lawsuit claim?
Potential claimants include Type 1 and Type 2 diabetics who used Dexcom G6 or G7 CGMs and suffered hypoglycemia, hyperglycemia, DKA, seizures, loss of consciousness, or hospitalization due to inaccurate device readings; families of patients who died while relying on a Dexcom CGM; and investors who purchased DXCM securities between January 8, 2024, and September 17, 2026, and suffered losses. Dexcom ceasing G6 production on July 1, 2026, does not affect the legal standing of patients injured before that date.
What is the current status of In re: Dexcom CGM Litigation?
As of the publication of this post in July 2026, In re: Dexcom CGM Litigation, No. 3:25-cv-02565-BJC-JAC, is pending in the U.S. District Court for the Southern District of California. The court consolidated five federal cases on May 15, 2026. Competing motions to appoint interim class counsel, filed May 29, 2026, are fully briefed and awaiting the court’s ruling. A joint status report is due August 19, 2026. No global settlement has been announced, and an MDL petition has been identified as a potential next step if class certification is denied.
What damages can Dexcom lawsuit plaintiffs recover?
Damages in the Dexcom lawsuit depend on the severity of each plaintiff’s injuries and circumstances. Consumer class action plaintiffs may seek compensation for medical expenses, out-of-pocket device costs, and related economic losses. Wrongful death plaintiffs may pursue damages for funeral costs, loss of financial support, and loss of companionship under applicable state law. Severely injured individuals may also seek compensation for pain and suffering, lost wages, and ongoing medical care. Investor plaintiffs in the securities case seek damages representing the difference between artificially inflated purchase prices and the actual value of DXCM securities. No settlement amounts have been publicly announced as of July 2026.
This content is provided for informational purposes only and does not constitute legal advice or create an attorney-client relationship.
Related reading: Pharmacy Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: General Surgery Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.